AXSM Axsome Therapeutics (AXSM) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001579428
Form 144 · 3
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
304
13F, latest reported quarter
Conversions, 180 days
12
Codes C/M, not in net · $1.0M priced
What the filings say about AXSM
Insiders, 180 days
-$50.0M net sold
6 sellers · 6% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$12.6M
3 notices
Axsome Therapeutics insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Axsome Therapeutics, Inc. insiders sold a net $50.0M of stock across 86 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.
Insider
Filed
Shares
Value
Since filing
Context
- 12 earlier Form 4 trades (code P or S) here by this insider (12 sales), the last on May 5, 2026.
- 1 other insider sold within 30 days.
- 304 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Operating Officer Jacobson Mark L. sold about $2.1M of AXSM under a 10b5-1 plan on Sep 3, 2026; 1 other insider sold within 30 days and 304 funds added in the latest 13F quarter.Context
- 19 earlier Form 4 trades (code P or S) here by this insider (19 sales), the last on Aug 5, 2026.
- The trade is 64.5% of the 7,229 shares held after it.
- 1 other insider sold within 30 days.
- 304 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer TABUTEAU HERRIOT sold about $997.0K of AXSM on Aug 6, 2026; 1 other insider sold within 30 days and 304 funds added in the latest 13F quarter.Context
- 18 earlier Form 4 trades (code P or S) here by this insider (18 sales), the last on Jul 1, 2026.
- The trade is 622.5% of the 7,229 shares held after it.
- 1 other insider sold within 30 days.
- 304 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer TABUTEAU HERRIOT sold about $9.5M of AXSM on Aug 5, 2026; 1 other insider sold within 30 days and 304 funds added in the latest 13F quarter.Context
- 17 earlier Form 4 trades (code P or S) here by this insider (17 sales), the last on Jun 9, 2026.
- The trade is 687.0% of the 7,229 shares held after it.
- 4 other insiders sold within 30 days.
- 304 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer TABUTEAU HERRIOT sold about $11.9M of AXSM on Jul 1, 2026; 4 other insiders sold within 30 days and 304 funds added in the latest 13F quarter.Context
- 11 earlier Form 4 trades (code P or S) here by this insider (1 buy, 10 sales), the last on Jun 10, 2026.
- The trade is 0.5% of the 58,367 shares held after it.
- 4 other insiders sold within 30 days.
- 304 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director JEFFS ROGER sold about $71.2K of AXSM on Jun 11, 2026; 4 other insiders sold within 30 days and 304 funds added in the latest 13F quarter.86 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$50.0M over 180 days
-$12.6M over 90 days · -$34.4M of it by a 10%+ holder
below 94% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
304 funds bought in last quarter
more than 95% of Pharma & Biotech
Revenue
+65.5% year over year
more than 81% of Pharma & Biotech
Margin
-28.7% net margin
more than 55% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
7.4% of the float short (float per yahoo 2026-10-26) · 4.4 days to cover · settled 2026-09-30
more than 57% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch AXSM
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+11.1%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns AXSM: institutional holders (13F)
13F holdings, latest reported quarter
3,103,708 sh
$759.7M
1,983,514 sh
$485.5M
1,965,086 sh
$481.0M
1,671,684 sh
$409.2M
1,539,163 sh
$376.7M
Congress trades in AXSM
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
AXSM planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Mark Jacobson
Filed 2026-09-03
$2.1M
Herriot Tabuteau
Filed 2026-08-06
$979.2K
Herriot Tabuteau
Filed 2026-08-05
$9.6M
Herriot Tabuteau
Filed 2026-07-01
$12.0M
AXSM mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Invesco Dorsey Wright Healthcare Momentum ETF
$9.7M position · as of 2026-07-31
4.1%
First Trust NYSE Arca Biotechnology Index Fund
$104.3M position · as of 2026-06-30
3.7%
AlphaCentric Life Sciences and Healthcare Fund
$1.6M position · as of 2026-06-30
3.4%
F/m Emerald Life Sciences Innovation ETF
$3.0M position · as of 2026-05-31
2.8%
Royce Smaller-Companies Growth Fund
$6.4M position · as of 2026-06-30
2.7%
iShares U.S. Pharmaceuticals ETF
$27.5M position · as of 2026-06-30
2.4%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
29 registered trials, 12 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
1
Phase 1
0 active
2
Phase 2
0 active
22
Phase 3
10 active
2
Phase 4
1 active
1
Not applicable
1 active
1
Multi-phase
0 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Executive pay vs shareholder return
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$10.3M
$33.8M
$3.6M
+124%
+25%
2024
$10.4M
$10.1M
$3.6M
+4%
-7%
2023
$9.9M
$9.6M
$3.6M
-2%
-6%
2022
$8.3M
$28.0M
$3.2M
-5%
-10%
2021
$8.1M
-$11.1M
$4.5M
-54%
+0%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $50.0M sold by insiders over 180 days, 304 funds added last quarter, $12.6M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
AXSM financials
Revenue growth
+65.5%
XBRL, annual
Net margin
-28.7%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$776.6M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM AXSM
| FY Dec 2025 | $638.5M |
| FY Dec 2024 | $385.7M |
| FY Dec 2023 | $270.6M |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | $218.4M |
| Mar 2026 | $191.2M |
| Dec 2025 | $196.0M |
| Sep 2025 | $171.0M |
| Jun 2025 | $150.0M |
| Mar 2025 | $121.5M |
| Dec 2024 | $118.8M |
| Sep 2024 | $104.8M |
At each fiscal year end
Single quarter
Net margin, TTM
-24.7%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM AXSM
| FY Dec 2025 | -28.7% |
| FY Dec 2024 | -74.5% |
| FY Dec 2023 | -88.4% |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | -23.5% |
| Mar 2026 | -33.8% |
| Dec 2025 | -14.6% |
| Sep 2025 | -27.6% |
| Jun 2025 | -32.0% |
| Mar 2025 | -48.9% |
| Dec 2024 | -63.1% |
| Sep 2024 | -61.7% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$72.0M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM AXSM
| FY Dec 2025 | -$93.9M |
| FY Dec 2024 | -$128.7M |
| FY Dec 2023 | -$145.7M |
| FY Dec 2022 | -$117.2M |
| FY Dec 2021 | -$108.5M |
| Jun 2026 | -$33.4M |
| Mar 2026 | -$20.8M |
| Dec 2025 | -$18.7M |
| Sep 2025 | $988.0K |
| Jun 2025 | -$32.4M |
| Mar 2025 | -$43.7M |
| Dec 2024 | -$26.2M |
| Sep 2024 | -$18.7M |
At each fiscal year end
Single quarter
Debt to equity
2.26x
long-term 2026-06-30 plus current 2026-06-30; equity 2026-06-30
Debt to equity AXSM
| FY Dec 2025 | 2.13x |
| FY Dec 2024 | 3.17x |
| FY Dec 2023 | 0.97x |
| FY Dec 2022 | 0.92x |
| FY Dec 2021 | 3.56x |
| Jun 2026 | 2.26x |
| Mar 2026 | 3.44x |
| Dec 2025 | 2.13x |
| Sep 2025 | 2.55x |
| Jun 2025 | 2.57x |
| Mar 2025 | 3.41x |
| Dec 2024 | 3.17x |
| Sep 2024 | 2.01x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-0.38x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Cash flow to debt AXSM
| FY Dec 2025 | -0.50x |
| FY Dec 2024 | -0.71x |
| FY Dec 2023 | -0.79x |
| FY Dec 2022 | -1.16x |
| FY Dec 2021 | -1.95x |
| Jun 2026 | -0.38x |
| Mar 2026 | -0.38x |
| Dec 2025 | -0.50x |
| Sep 2025 | -0.54x |
| Jun 2025 | -0.64x |
| Mar 2025 | -0.65x |
| Dec 2024 | -0.71x |
| Sep 2024 | -0.71x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-245.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity AXSM
| FY Dec 2025 | -252.1% |
| FY Dec 2024 | -231.6% |
| FY Dec 2023 | -159.2% |
| FY Dec 2022 | -299.0% |
| FY Dec 2021 | -201.5% |
| Jun 2026 | -245.1% |
| Mar 2026 | -349.4% |
| Dec 2025 | -252.1% |
| Sep 2025 | -275.5% |
| Jun 2025 | -280.7% |
| Mar 2025 | -282.2% |
| Dec 2024 | -231.6% |
| Sep 2024 | -171.6% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-27.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets AXSM
| FY Dec 2025 | -29.1% |
| FY Dec 2024 | -49.7% |
| FY Dec 2023 | -52.0% |
| FY Dec 2022 | -89.3% |
| FY Dec 2021 | -95.2% |
| Jun 2026 | -27.4% |
| Mar 2026 | -28.7% |
| Dec 2025 | -29.1% |
| Sep 2025 | -37.3% |
| Jun 2025 | -41.6% |
| Mar 2025 | -48.7% |
| Dec 2024 | -49.7% |
| Sep 2024 | -53.5% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital AXSM
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-62.2%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed AXSM
| FY Dec 2025 | -51.4% |
| FY Dec 2024 | -71.2% |
| FY Dec 2023 | -67.8% |
| FY Dec 2022 | -120.0% |
| FY Dec 2021 | -109.7% |
| Jun 2026 | -62.2% |
| Mar 2026 | -55.2% |
| Dec 2025 | -51.4% |
| Sep 2025 | -63.0% |
| Jun 2025 | -69.4% |
| Mar 2025 | -71.6% |
| Dec 2024 | -71.2% |
| Sep 2024 | -71.9% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing AXSM
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$7.4B
market value at close 2026-10-26 on 2026-08-03 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
Enterprise value AXSM
| FY Dec 2025 | $9.1B |
| FY Dec 2024 | $4.0B |
| FY Dec 2023 | $3.6B |
| FY Dec 2022 | $3.2B |
| FY Dec 2021 | $1.4B |
| Jun 2026 | $12.5B |
| Mar 2026 | $8.5B |
| Dec 2025 | $9.1B |
| Sep 2025 | $5.9B |
| Jun 2025 | $5.0B |
| Mar 2025 | $5.6B |
| Dec 2024 | $4.0B |
| Sep 2024 | $4.2B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-1.0%
TTM free cash flow over market value at close 2026-10-26
FCF yield AXSM
| FY Dec 2025 | -1.0% |
| FY Dec 2024 | -3.1% |
| FY Dec 2023 | -3.9% |
| FY Dec 2022 | -3.5% |
| FY Dec 2021 | -7.6% |
| Jun 2026 | -0.6% |
| Mar 2026 | -0.8% |
| Dec 2025 | -1.0% |
| Sep 2025 | -1.7% |
| Jun 2025 | -2.4% |
| Mar 2025 | -2.1% |
| Dec 2024 | -3.1% |
| Sep 2024 | -3.1% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing AXSM
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $638.5M | $385.7M | $270.6M | $50.0M |
| Operating income | -$166.8M | -$280.6M | -$231.8M | -$179.8M |
| Net income | -$183.2M | -$287.2M | -$239.2M | -$187.1M |
| EPS (diluted) | -3.68 | -5.99 | -5.27 | -4.60 |
| Operating cash flow | -$93.4M | -$128.4M | -$145.1M | -$116.5M |
| Cash | $322.9M | $315.4M | $386.2M | $200.8M |
| Long-term debt | $117.7M | $180.7M | $178.1M | $94.3M |
SEC XBRL, fiscal years, as known on 2026-10-27
AXSM Stock Sonar score 6/7 axes
Find similar shapesCompareAXSM ranks highest on institutional and government (95th percentile) and growth (81st), and lowest on insider conviction (2nd), among Pharma & Biotech peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
AXSM filings, in plain words
Are Axsome Therapeutics insiders buying or selling AXSM?
In the 180 days to 2026-10-27, Axsome Therapeutics insiders were net sellers, a net $50.0M across purchases and sales reported on Form 4, by 6 sellers.
Are there planned insider sales of AXSM?
Yes. 3 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-27, covering $12.6M of stock; the latest, by Mark Jacobson, was filed 2026-09-03.
Read the full summary
In the 180 days to 2026-10-27, Axsome Therapeutics insiders were net sellers of AXSM, a net $50.0M across purchases and sales reported on Form 4 by 6 sellers. Most of that figure, $34.4M, came from a holder of 10% or more rather than an officer or director. 6% of the 16 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Insiders filed 3 Form 144 notices of intent to sell in the 90 days to 2026-10-27, covering $12.6M of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
